<DOC>
	<DOCNO>NCT00707187</DOCNO>
	<brief_summary>Purpose study evaluate effectiveness safety new investigational dur , IC351 . Study design gather information regard possible usefulness IC351 treatment several blood vessel feature scleroderma . This include Raynaud phenomenon well vaginal dryness discomfort associate scleroderma</brief_summary>
	<brief_title>Trial IC351 Female Scleroderma Patients With Raynaud 's Sexual Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Female diagnosis scleroderma Stable sexual relationship male partner sexually active Raynaud phenomenon least 6 time per week Willing attempt sexual activity 1/month study period Severe internal organ problem relate scleroderma Other gynecologic problem Serious depression Receiving experimental Raynaud treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>systemic sclerosis</keyword>
	<keyword>scleroderma</keyword>
	<keyword>raynaud phenomenon</keyword>
</DOC>